Abstract: Small cell lung cancer (SCLC) is a unique malignant tumor with a highly multiplying pathological histological feature. In addition, SCLC differs from other cell types of lung cancer in terms of ultrastructure, endocrinology, cytogenetics, cytokinetics and clinical features, and its short multiplication time has been clinically confirmed by rapid growth, rapid progression of symptoms and signs, and early and widespread spread Over the past 20 years, SCLC has been shown to be a unique malignancy for all forms of non-handed small cell lung cancer (SCLC), with highly multiplying pathological histological features, in addition to ultrastructure, endocrinology, cytogenetics, cytokinetics, and clinical features that distinguish SCLC from other cell types of lung cancer, and its short multiplication time has been clinically demonstrated by The rapid growth, rapid progression of signs and symptoms, and early and widespread spread of SCLC have been proven to be highly sensitive to various forms of nonsurgical therapies over the past 20 years. The recent outcomes of 71 patients with SCLC admitted to our hospital from January 1999 to December 2003 who could be evaluated for efficacy are summarized below. Abstract: Small cell lung cancer (SCLC) is a unique malignant tumor with reproductive pathological histological features. In addition, SCLC differs from other cell types of lung cancer in ultrastructure, endocrinology, cytogenetics, cytokinetics and clinical features, and its short ploidy time has been clinically confirmed by rapid growth, rapid progression of symptoms and signs, and early and extensive spread Over the past 20 years, SCLC has been shown to be resistant to various forms of non-hand… Small cell lung cancer (SCLC) is a unique malignant tumor with reproductive pathological histological features. In addition, SCLC differs from other cell types of lung cancer in terms of ultrastructure, endocrinology, cytogenetics, cytokinetics and clinical features, and its short ploidy time has been confirmed by rapid clinical growth, rapid progression of symptoms and signs, and early and widespread spread in the last In the past 20 years, SCLC has been proven to be highly sensitive to various forms of non-surgical therapies. The recent outcomes of 71 SCLC patients admitted to our hospital from January 1999 to December 2003 with evaluable outcomes are summarized as follows 1. According to the staging criteria of SCLC developed by the United States Veterans Hospital, the limited stage (LD) refers to the lesion confined to one side of the chest, mediastinum, oblique angle muscle and supraclavicular lymph nodes, but there can be no The limited stage (LD) refers to a lesion limited to one side of the chest, mediastinum, oblique muscle and supraclavicular lymph nodes, but without significant superior vena cava compression, vocal cord paralysis and pleural effusion. The extensive stage (ED) refers to patients who exceed the above-mentioned range. In this group, 37 cases of LD accounted for 52.11%, 34 cases of ED accounted for 47.89%, 65 cases (91.55%) had the first intrapulmonary manifestation, including 64 cases (90.14%) of cough, 38 cases (53.52%) of blood in sputum, 32 cases (45.07) of chest pain, 25 cases (35.21%) of breath-holding, 7 cases (9.86%) of hoarseness, and 6 cases (8.45%) had the first extrapulmonary manifestation. 8.45%), including 4 cases of fever, 1 case each of headache and lumbago. At the time of admission, 11 cases (15.49%) were clinically diagnosed with distant metastases, including 4 brain metastases, 2 adrenal metastases, 2 spinal metastases, and 1 each of liver, iliac bone and skin metastases. All patients had routine chest X-ray (front and side), ultrasound of liver, spleen and adrenal glands, ECG, routine blood and liver and kidney function tests before and after treatment, and some patients had chest CT, cranial CT and iliac bone X-ray. 1.2 Treatment Among 71 patients, 32 cases were treated with chemotherapy alone, 31 cases were treated with chemotherapy followed by radiotherapy, 4 cases were treated with radiotherapy alone, 4 cases were treated with surgery plus chemotherapy, and 1 of them was treated with radiotherapy. 1.2.1 Main chemotherapy regimen (1) COMC: CTX 800-1000mg/dose, iv, days 1 and 8, VCR 2mg/dose, iv, days 1 and 8, MTX 20mg/dose, iv or im, days 3, 5, 10 and 12, CCNU 100-150mg, PO, repeatable after 6 weeks; (2) comvp: com as above. VP-16100mg/dose, by drip, days 3 to 7. (3)COA:CO as above, ADM50mg/dose, iv, day 1. (4)COP:CO as above, DDP50mg/dose iv, days 1 to 3; (5)EP:DDP50mg/dose, iv, days 1 to 3, VP-16100mg/dose, by drip, days 4 to 8. (6)EAP:EP as above. ADM50mg/dose, iv, day 1. The patients who were treated with DDP chemotherapy were routinely treated with hydration and antiemetic treatment with gastrofacial and benadryl, and four patients were treated with carboplatin instead of DDP. all of the above regimens were given in 21-day cycles, and 2-3 cycles were given as one course of treatment. All patients received more than 1 course of chemotherapy. 1.2.2 Radiotherapy External 60 Co alpha radiation was applied to the primary foci of the lung, both hilum, the whole mediastinum, and both supraclavicles. Radiotherapy method:5 times per week. Each time 20 Gy, the mediastinal volume DT up to 40 Gy/4 weeks should avoid the spinal cord, so that the total primary foci DT up to 60 Gy/6 weeks, the supraclavicular with metastases DT 60 Gy/week, the prophylactic irradiation DT 40-50 Gy/4 weeks. For the 4 cases with brain metastases at admission, the whole brain was irradiated with 40 Gy, and then the field was narrowed to align the metastases with an additional 20 Gy. For those with skeletal and skin metastases, 60 Co and deep X-ray were used to irradiate the lesions with 30-50 Gy, respectively. radiotherapy was administered 0-2 weeks after 1 course of combined chemotherapy. 1.3 Efficacy assessment criteria Complete remission (CR): complete disappearance of lesions was seen for more than 1 month. Partial remission (PR): The product of the largest diameter of the tumor and its perpendicular diameter is reduced by more than 50% for more than 1 month. Stable (SD): The mass shrinks less than 50% or does not increase more than 25%. Progressive (PD): the mass is more than 25% enlarged or new lesions appear. Toxic reactions were evaluated according to WHO standards.